Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

January 31, 2000

Study Completion Date

October 31, 2006

Conditions
Multiple Myeloma
Interventions
DRUG

pamidronate

Trial Locations (14)

2730

Department of Haematology, Herlev University Hospital, Herlev

9000

Department of Haematology B, Aalborg Hospital, University of Aarhus, Aalborg

DK-8000

Hæmatologisk afd., Århus Universitetshospital, Aarhus

DK-2100

Department of Hematology L, Rigshospitalet, København Ø

N-5021

Hematologisk seksjon, med avd, Haukeland Universitetssykehus, Bergen

N - 0407

Hematologisk avdeling Ullevål Sykehus, Oslo

N-9038

Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge, Tromsø

N-7006

Hematologisk seksjon, St.Olav Hospital, Trondheim

SE-416 85

Sahlgrenska Universitetsjukhuset Östra, Gothenburg

SE-581 85

Hematologkliniken, Universitetssjukhuset, Linköping

SE-205 02

Medicinklin, Universitetssjukhuset MAS,, Malmo

SE-70185

Medicinkliniken, Universitetssjukhuset, Örebro

SE-901 85

Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus, Umeå

SE-751 85

Medicinklinikken Akademiska sjukhuset, Uppsala

All Listed Sponsors
collaborator

Nordic Cancer Union

OTHER

lead

Nordic Myeloma Study Group

OTHER

NCT00376883 - Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month | Biotech Hunter | Biotech Hunter